Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy
Psychoactives – November 02, 2025
Source: OpenAlex
Summary
Psilocybin holds significant therapeutic potential for mood and cognitive dysregulation, yet its efficacy may be profoundly influenced by sex hormones. Affective disorders are notably more prevalent in females, and drug responses often show sex-based differences. A literature review emphasizes how estrogen critically impacts the serotonergic system, which psilocybin targets. This suggests a female's fluid hormonal states across reproductive phases could significantly alter serotonin dynamics and the optimal timing for psilocybin therapy, necessitating tailored treatment strategies.
Abstract
Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitive, and affective dysregulation. These domains of function are regulated by the serotonergic system, which can be influenced by sex hormones, like estrogen and testosterone, and psychedelic compounds including psilocybin. Current evidence supports a higher prevalence of affective disorders in females, and a growing awareness of sex-based differences in response to drug therapy. Estrogen’s influence on serotonin physiology is an aspect that must be accounted for when planning a treatment regimen that includes a psychoactive drug such as psilocybin. A review of the current literature was conducted, and an analysis of how the fluid hormonal states in females across their different reproductive phases may impact serotonin dynamics, synaptic plasticity, and therapeutic timing of psilocybin use is discussed. Future research should focus on the influence of sex hormones on psychedelic-assisted therapy in the effort to further personalize treatment plans for these pathologies.